Inorganic Chemistry: What is the binding affinity of Iron (III) with EDTA and Deferoxamine?

EDTA has almost no affinity for iron and therefore no clinical benefit, deferoxamine is the treatment of choice for acute and chronic (e.g hemochromatosis) iron overload.  EDTA has been studied and used successfully to improve renal function in patients with impaired kidney function not due to lead toxicity(http://ndt.oxfordjournals.org/co...).  So while the mainstream medicine mantra is that EDTA is toxic to the kidneys, a double blind study has shown a  marked benefit in those with renal failure when treated with EDTA.

Reference: https://www.quora.com/Inorganic-Chemistry-What-is-the-binding-affinity-of-Iron-III-with-EDTA-and-Deferoxamine